ERCC1 Expression As a Predictive Marker of Cervical Cancer Treated with Cisplatin-based Chemoradiation

被引：1
|
作者：
Muallem, Mustafa Zelal [1 ]
Marnitz, Simone [3 ]
Richter, Rolf [1 ]
Koehler, Christhardt [4 ]
Sehouli, Jalid [1 ]
Arsenic, Ruza [2 ]
机构：
[1] Charite, Virchow Campus Clin, Dept Gynecol & Obstet, D-13353 Berlin, Germany
[2] Charite, Virchow Campus Clin, Inst Pathol, D-13353 Berlin, Germany
[3] Charite, Dept Radiooncol, D-13353 Berlin, Germany
[4] Charite, Dept Gynecol & Obstet, D-13353 Berlin, Germany
来源：
ANTICANCER RESEARCH | 2014年 / 34卷 / 1A期
关键词：
ERCC1; protein; cervical cancer; chemoradiation; cisplatin; immunohistochemistry staining; NUCLEOTIDE EXCISION-REPAIR; SQUAMOUS-CELL CARCINOMA; ENDONUCLEASE ERCC1-XPF; MAMMALIAN-CELLS; SURVIVAL; RECOMBINATION; THERAPY; HEAD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: The purpose of the present study was to evaluate the correlation between repair cross-complementing group-1 (ERCC1) status and the outcome of platin-based chemoradiation of locally advanced cervical cancer. Patients and Methods: Tumor specimens from 112 patients with locally advanced cervical cancer were evaluated for ERCC1 expression. The outcome of these patients was retrospectively assessed in correlation with ERCC1 expression. Results: Increased expression of ERCC1 correlates with a better prognosis of cervical cancer. The 2-year overall survival was 68.6% in the group with low H-score for ERCC-1 and gradually increased in the intermediate and high H-score groups to 71.7% and 90.7%, respectively. Conclusion: The present study did not confirm the correlation of low levels of ERCC1 expression with unfavorable outcomes of patients with locally advanced cervical cancer treated with platin-based radiochemotherapy.
引用
收藏
页码：401 / 406
页数：6
相关论文
共 50 条
  • [1] ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
    H J Jun
    M J Ahn
    H S Kim
    S Y Yi
    J Han
    S K Lee
    Y C Ahn
    H-S Jeong
    Y-I Son
    J-H Baek
    K Park
    British Journal of Cancer, 2008, 99 : 167 - 172
  • [2] ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
    Jun, H. J.
    Ahn, M. J.
    Kim, H. S.
    Yi, S. Y.
    Han, J.
    Lee, S. K.
    Ahn, Y. C.
    Jeong, H-S
    Son, Y-I
    Baek, J-H
    Park, K.
    BRITISH JOURNAL OF CANCER, 2008, 99 (01) : 167 - 172
  • [3] Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation
    Ciaparrone, Marco
    Caspiani, Orietta
    Bicciolo, Giulio
    Signorelli, Diego
    Simonelli, Ilaria
    de Campora, Luca
    Mazzarella, Giorgio
    Mecozzi, Antonella
    Pianelli, Curzio
    Camaioni, Angelo
    Catalano, Piera
    Pasqualetti, Patrizio
    Fabiano, Alfredo
    Radici, Marco
    Marmiroli, Luca
    Corsi, Domenico Cristiano
    ONCOLOGY, 2015, 89 (04) : 227 - 234
  • [4] Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy
    Huang, Pei-Yu
    Li, Yan
    Mai, Hai-Qiang
    Luo, Rong-Zhen
    Cai, Yu-Chen
    Zhang, Li
    ORAL ONCOLOGY, 2012, 48 (10) : 964 - 968
  • [5] ERCC1 Expression and Outcomes in Head and Neck Cancer Treated with Concurrent Cisplatin and Radiation
    Hayes, Mose
    Lan, Cynthia
    Yan, Jingsheng
    Xie, Yang
    Gray, Toby
    Amirkhan, Robin H.
    Dowell, Jonathan E.
    ANTICANCER RESEARCH, 2011, 31 (12) : 4135 - 4139
  • [6] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    De Dosso, Sara
    Zanellato, Elena
    Nucifora, Martina
    Boldorini, Renzo
    Sonzogni, Angelica
    Biffi, Roberto
    Fazio, Nicola
    Bucci, Eraldo
    Beretta, Ottavio
    Crippa, Stefano
    Saletti, Piercarlo
    Frattini, Milo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 159 - 165
  • [7] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    Sara De Dosso
    Elena Zanellato
    Martina Nucifora
    Renzo Boldorini
    Angelica Sonzogni
    Roberto Biffi
    Nicola Fazio
    Eraldo Bucci
    Ottavio Beretta
    Stefano Crippa
    Piercarlo Saletti
    Milo Frattini
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 159 - 165
  • [8] Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
    Yun, Jina
    Kim, Kyoung-Mee
    Kim, Seung Tae
    Kim, Jung-Hoon
    Kim, Jung A.
    Kong, Jee Hyun
    Lee, Soo Hyeon
    Won, Young-Woong
    Sun, Jong-Mu
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2010, 42 (02): : 101 - 106
  • [9] ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation
    De Castro, Gilberto, Jr.
    Pasini, Fatima Solange
    Coelho Siqueira, Sheila Aparecida
    Ferraz, Alberto Rossetti
    Villar, Rosangela Correa
    Longo Snitcovsky, Igor Moyses
    Honda Federico, Miriam Hatsue
    ONCOLOGY REPORTS, 2011, 25 (03) : 693 - 699
  • [10] ERCC1 mRNA Expression as a Postoperative Prognostic Marker in Extrahepatic Bile Duct Cancer
    Uemura, Shuichiro
    Kuramochi, Hidekazu
    Higuchi, Ryota
    Nakajima, Go
    Yamamoto, Masakazu
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S627 - S633
12345